Inflammation is a central element of atherogenesis. Innate pathways contribute to vascular inflammation. However, the initial molecular process (es) 
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-blue boxes and blue arrow). Among the exogenous activation pathways are innate mechanisms, such as toll-like-receptors (TLRs), including the endotoxin receptors TLR-2 and TLR-4. On the other hand (endogenous) innate cytokines, such as interleukin (IL)-1, IL-6 or tumour necrosis factor (TNF), or even autoimmune triggers can activate the cells. Cytokines are potent regulators of cardiovascular cell functions, and therefore can potently influence homeostasis within the vessel wall. Consequently, SMCs can actively contribute to the inflammatory status in the vessel wall by producing these potent mediators or by responding to them. The cell interaction of vessel wall cells (i.e. ECs or SMCs) with invading cells (monocytes, T cells, mast cells) by cytokines may contribute to vascular inflammation. Cytokines may cause increased accumulation of monocytes, lowdensity lipoprotein (LDL) and extracellular matrix (ECM) in the vessel wall. If not brought back to physiological levels, cell and ECM accumulation provides an 'innate-immunovascular-memory' resulting in an ever-growing response to anew invasion. In this review, we discuss the role of selected inflammatory and innate pathways in atherogenesis, and point to the importance of cytokine-mediated interaction of vascular and invading cells.

Atherosclerosis -overview
General remarks
Atherosclerosis is a multifactorial disease, the pathogenesis of which is still not completely understood. Among the classical risk factors are diet, obesity, metabolic syndrome, diabetes, hypercholesteremia, smoking, hypertension and shortcomings in physical activity. It is now well accepted that inflammatory pathways are involved in the development and progression of atherosclerosis.
Thus, formerly regarded as a lipid disease, more recently inflammation is supposed to be an important factor in atherogenesis [1, 2] . Fig. 1 -red arrows) [3] . On the other hand, 'patrolling' [4, 5] [7] . Based on the 'response to injury' proposal by Russel Ross [1] 
Early atherosclerosis
Changes in the vessel wall in early atherosclerosis may start with altered endothelial function (EC dysfunction), occasional endothelial denudation, vasoconstriction, enhanced procoagulation, increased leucocyte adhesion or enhanced plasma protein leakage (compare
Endogenous activators
Among the endogenous activators possibly involved in atherogenesis [10] [7, 13] . However, it is still a matter of debate, which monocyte subset is functionally more important [14] [15] [16] [19] [21] 
PAMP and DAMP
Many infectious 'agents' activate the cells via the PRR by pathogen-associated molecular pattern (PAMP) containing molecules. PAMPs are highly conserved structures of microorganisms, or other 'danger signals', indicating 'a need for' defence. PRR can also detect endogenous signals, derived from damaged cells, containing damage-associated molecular patterns (DAMPs). Among the PRR activation pathways are the pentaxin or pentraxin molecules, including the acute phase molecules and serum proteins C-reactive protein (CRP) or serum amyloid P (SAP). The PAMPs and DAMPs are involved in pathogen recognition and removal of apoptotic cells. On the other hand, there are PRRs present in the cytosol of cells. They include the nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs)
Pentraxins
The pentraxins (or pentaxins) are soluble proteins present in the plasma. CRP and SAP belong to the short pentraxins, whereas PTX3 is the prototype of a long pentraxin [22] . [22, 23] .
The short pentraxins are mainly produced in the liver, whereas PTX3 is produced by many cells including monocytes, fibroblast or vascular cells, and its activation is induced by inflammatory compounds, such as IL-1, TNF, LPS or oxidized LDL (oxLDL). PTX3 is a multifunctional protein; it contributes to activation of ECM deposition and inflammation by binding to various ligands, including complement factors, ECM, growth factors, membrane components or pathogens. Subsequently, PTX3 activates the complement cascade, as well as the removal of pathogens or cellular debris. This molecule has been detected in the atherosclerotic plaque in monocytes, EC and in SMC. Very recently this molecule has been described as a marker of inflammation in patients with heart failure and myocardial infarction
NOD-like proteins/receptors (NLRs)
The NOD-like proteins/receptors belong to a group of cytoplasmatic proteins containing a nucleotide-binding oligomerization domain (NOD) [21, 24] [25, 26] [41, 42] . It is also found in a functionally active form on cardiovascular cells, such as ECs, SMCs and heart cells [43, 44] . In contrast to the IL-1␣ precursor, the IL-1␤ precursor is not (or million-fold less) active [45] . In SMC IL-1␤ is present, but not processed [46] ; however, leucocytes can activate the precursor present in SMC in a cell number dependent fashion [47] . [50] , transforming growth factor (TGF) [51] or endothelin [52] , may further enhance the inflammatory load in the vessel wall. In addition, IL-1 and TNF also affect functions separate from inflammation, such as contraction of vascular cells [53] . [54] . The enhanced amount of ECM is thought to contribute to initiation of atherosclerosis through enhanced lipoprotein retention (response to retention hypothesis) [55] . Cytokine-mediated regulation of enzyme [56] and/or matrix production [57] [58] . ECM components can increase the retention of LDL or lipoproteins [59] . In addition, components of the ECM can also bind a variety of cytokines [60] . ECM [70] . [72] . [77] . IL-6 activates the production of acute phase response proteins in hepatocytes. [78] . IL-6 is produced by a variety of cells, including monocytes [79] , epithelial cells [80] and cardiovascular cells [49, 81] . [83] . CRP also induced MCP-1 and IL-6 production in SMCs [84] . An autocrine loop for stimulation of SMCs by endogenous IL-6, involving transsignalling mechanisms, has also been suggested [85] .
. They bind pathogen-derived molecules and either activate mitogen-activated protein kinases or NF-B (NOD1; NOD2), or caspase-1 (NALP1 [NACHT, LRR and PYD containing protein]; NALP3; IPAF [ICE-protease-activating factor]) by initiating the assembly of the inflammasome. The latter is a multiprotein complex important for activation of IL-1, IL-18 and IL-33
may activate proliferation of the local smooth muscle cells, an effect which is probably mediated or amplified by induction of platelet-derived growth factor (PDGF). IL-1 also induces nitric oxide production in SMC, which may in turn contribute to regulation of proliferation. Activation of the production of many other molecules, including IL-6 [49], vascular endothelial growth factor (VEGF)
Activation of ECM production, its degradation and reassemblement is of great importance for atherogenesis. In human beings the development of a diffuse intimal thickening (DIT) has been suggested to be present before atherosclerosis develops
may be the initial step of this procedure, started by the innate mechanisms discussed above. In other words, upon a -still undefined -initial activation by innate pathways, ECM production is up-regulated in response to IL-1, TGF, PDGF or TNF stimulation in the vessel wall
TNF-␣ shares many characteristics with IL-1. It is a pleiotropic cytokine, it is also produced by cardiovascular cells, and it also can signal via NF-B. Like IL-1 it is also produced preferentially by monocytic cells. TNF is produced as a 26 kD membrane-associated molecule and transformed by a protease (TNF-converting enzyme, TACE, also known as ADAM17) into its 17 kD soluble form. It is binding to its receptor as a homotrimer. Depending on the presence of the TNF-receptor subtypes I (p55) or II (p75) it induces NF-B and/or the death pathway, or only the NF-B pathway, respectively. It is a member of a family of molecules, including CD40L, FasL or CD70, which are preferentially membrane bound. Their function in many cases needs cell-cell contact, and they are capable of signalling in two directions
Finally, investigating a homozygous IL-1ra knockout, instead of a heterozygous, MerhiSoussi and colleagues found massive inflammation and early mortality in the ApoE double-deficient mice [71]. They suggested that the ratio of IL-1 and IL-1ra may be of great importance for the development of atherosclerosis. Thus, TNF-␣ and IL-1 may contribute potently to atherosclerosis. In analogy, as discussed in the field of immunosenescence, multiple subsequent infectious or inflammatory incidents ('multiple hits') may cause an enhanced 'inflammatory/pathogen burden', resulting in enhanced risk of cardiovascular diseases
Monocyte chemoattractant protein-1 and fractalkine
IL-6 activates innate pathways and is produced by cardiovascular cells
Among the secondary cytokines produced in response to IL-1 or TNF-␣ IL-6 is of major interest, because this cytokine is an important activator of the acute phase response
Fig. 2 IL-6 'classical' signalling, IL-6 'trans-signalling' and inhibition of 'trans-signalling'. (A) In the classical signalling IL-6 binds to the membrane-bound IL-6 receptor. (B) In trans-signalling IL-6 binds to the soluble IL-6 receptor, previously released from some cells. This complex is interacting with membrane-associated gp130. In both, classical and trans-signalling, the signal-transducer gp130 is recruited and STAT3 phosphorylation is activated. This can be achieved by PKC-␦. Other signal pathways may also be activated (box with green double frame), resulting in STAT3 phosphorylation. Subsequently, STAT3 activates gene expression in the nucleus. Among the genes activated by IL-6 is SOCS3, a down-regulator of IL-6 signalling. Some additional genes and functions relevant for atherosclerosis are mentioned in the yellow box. (C) Inhibition of trans-signalling by soluble gp130. Soluble gp130 is generated by alternative splicing. This molecule can bind the complex of soluble IL-6 receptor and IL-6, but not IL-6 alone. Thus, soluble gp130 is a selective inhibitor of IL-6 trans-signalling. (D) The definitions of the different symbols are provided in the yellow
Functions of IL-6 important for atherogenesis
Besides the autocrine effect of IL-6 on SMC activation discussed above [85] , [86] , it may alter prostaglandin-E2 production [87] , stimulate SMC migration [88] or induce matrix metalloproteinase (MMP)-9 secretion or MMP-1 production [89] . Some clinical data also point to a role of IL-6 in cardiovascular diseases. Thus, IL-6 or CRP are of potential value as markers for cardiovascular diseases, such as coronary artery disease and atherosclerosis [90] , and the expression of IL-6 has been detected in the atherosclerotic lesion [91] .
stimulation of a number of SMC functions by IL-6 has been described. Importantly, IL-6 induced the proliferation of rat SMCs, but not in human aortic and venous SMCs (unpublished observation). It reduces the contractility of SMCs
Role of trans-signalling in cardiovascular inflammation
IL-6 trans-signalling is responsible for pro-inflammatory activities of IL-6. On its target cells IL-6 first binds to the membrane-associated IL-6 receptor (IL-6R). The complex of IL-6 and IL-6R associates with the signal-transducing membrane protein gp130, thereby inducing its dimerization and initiation of signalling (Fig. 1) [92]. The glycoprotein gp130 is expressed by all cells in the body, whereas IL-6R is mainly expressed by hepatocytes, monocytes/macrophages and some leucocytes. A naturally occurring soluble form of the IL-6R (sIL-6R), which has been found in vari-
ous body fluids, is preferentially generated by proteolysis of the membrane protein [93] and in human beings, but not in mice, by translation from an alternatively spliced mRNA [94] . Interestingly, the sIL-6R together with IL-6 stimulates cells, which only express gp130, a process, which has been named trans-signalling (Fig. 2 ) [95, 96] . Moreover, it has been shown that the sIL-6R strongly sensitizes target cells, which do express the membrane bound IL-6R [97] . Importantly, the autocrine loop for the stimulation of SMCs by IL-6, has been suggested to involve trans-signalling mechanisms [85] . The gp130 protein is also present in a soluble form in body fluids. In contrast to the IL-6 receptor it is preferentially produced following alternative splicing [98, 99] [100] .
IL-6 not only has pro-inflammatory properties but also has been shown to be involved in regenerative and metabolic functions [101, 102] . Although blockade of IL-6 is generally regarded to be beneficial in the case of chronic inflammatory states, in a model of inflammation-induced colon cancer it has recently been shown that IL-6 deficient mice were more inflamed [103] , suggesting that IL-6 also has anti-inflammatory activities [104] . [105, 106] , such as inflammatory bowel disease [107, 108] , peritonitis [109] , rheumatoid arthritis [110] and colon cancer [111, 112] . It was concluded that the pro-inflammatory activities of IL-6 are mainly executed via IL-6 trans-signalling [113] , pointing to a therapeutic potential of the sgp130Fc protein for the treatment of inflammatory diseases [114] . It [115] .
Using the recombinant sgp130Fc protein and mice transgenic for sgp130Fc, it has been shown that IL-6 trans-signalling, but not IL-6 classic signalling via the membrane bound IL-6R, is needed for the maintenance of chronic inflammatory states
Animal experiments suggest a role for the IL-6 system in atherosclerosis
Evidence for an involvement of IL-6 in atherosclerosis is provided by experiments injecting IL-6 to several types of male mice fed normal or high fat diets [116] . 
Cytokine-mediated interaction of vessel wall cells and leucocytes
Vessel wall cells, in addition to the classical cytokine producers, the leucocytes, can also produce cytokines, such as IL-1 or IL-6 [49, 122] Fig. 1 ). [123] . Monocytes and ECs also produce PDGF upon interaction, probably by an IL-1-and TNFdependent pathway [124] . Interaction of ECs and monocytes also results in production of the potent cell activator granulocyte macrophage-colony stimulating factor. It can also lead to reduced nitric oxide production, and lower dilatation [125] . Monocyte-EC cocultures also produced enhanced tissue factor, which may be of importance for thromboembolic problems. Also of potential importance for later steps in atherosclerosis, MMP-1 is up-regulated in monocyte-EC cocultures [126] . [127] . It has also been described that the proliferation, collagen production or chemokine production, was elevated upon EC-SMC interaction.
Endothelial cell (EC)-monocyte interaction
Smooth muscle cell (SMC)-EC interaction
Upon migration of SMCs into the sub-endothelial space interaction of ECs and SMCs may result in further activation. In a model using microporous membranes the adhesion of monocytes was increased upon coculture of ECs with SMCs
TGF-␤ production is regulated depending on the type of coculture (bilayer or mix), and may have impact on adhesion molecule expression on SMC, or nitric oxide production.
SMC-monocyte and SMC-T cell interaction
Following invasion of the neointima monocytes may interact with the local SMCs in various ways. Enhanced VEGF was observed in monocyte-SMC interaction, which was partially mediated by soluble cytokines, such as IL-6 [128] . PDGF-and hepatocyte growth factor-production were also enhanced in coculture experiments [129] . These molecules possibly contribute to cell growth in the developing plaque. However, interaction may also activate counter-balancing mechanisms [130] . On the other hand, the production of enzymes was enhanced in coculture models [89] . Furthermore, an enhanced nitric oxide production upon interaction was detected [131] . [132] . Very recently, we have shown a dramatic up-regulation of IL-6 and MCP-1 production in a SMC-mononuclear cell coculture, which was mediated by soluble factors; however, the leucocytes involved were monocytes and not T cells [133] . This synergistic cytokine production was potently reduced by antiphlogistics and statins [134] . Fig. 1 Fig. 1 -red 
Not only monocyte-SMC interactions have been studied. In the later phases of atherosclerosis T cells are potently involved. Thus, it has been shown that T cells and SMCs of several tissues interact in various ways
As indicated above, experimental evidence exists for a variety of cytokine-mediated interactions of immigrant cells and vascular vessel wall cells. These interactions and the resulting alterations in homeostasis (compare
